Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Intranasal Stimulator Increases Tear Production

By HospiMedica International staff writers
Posted on 09 May 2017
A noninvasive, handheld device delivers neurostimulation to the nasal cavity via disposable tips in order to increase tear production.

The TrueTear intranasal tear neurostimulator consists of a rechargeable handheld unit and disposable hydrogel tips, which are inserted into the nasal passage and used to stimulate the trigeminal nerve via the afferent ethmoid nasal pathway. More...
The neurostimulation device allows dry eye patients not only to treat themselves by activating their own tear production system, but also to activate other glands that secrete lipids and proteins, thus increasing the mucin and aqueous layers of the tear film.

Two clinical studies involving 145 aqueous deficient dry eye adult patients showed positive safety and effectiveness of the device in the increase of tear production. The direct clinical benefit of temporarily increasing tear production as a therapy for dry eye disease was not assessed as part of the clinical trials, but all device-related adverse events were mild in nature. The TrueTear intranasal tear neurostimulator is a product of Allergan, and has been approved by the U.S. Food and Drug Administration (FDA).

“TrueTear represents a technological breakthrough for eye care professionals as it delivers an effective, non-invasive and drug-free way to temporarily increase tear production,” said David Nicholson, chief R&D officer at Allergan. “As an innovator in eye care, we are continually looking for new products to offer through our portfolio, and TrueTear represents the next step forward.”

“In clinical trials, TrueTear demonstrated increased tear production upon stimulation of the nasal cavity,” said professor of ophthalmology John Sheppard, MD, MSc, of Eastern Virginia Medical School (Norfolk, USA). “Interestingly, neurostimulation has been used as an approach for a wide variety of disorders for more than 30 years. TrueTear is the first of its kind to provide a temporary increase in tear production in this way.”

Of more than 100 million dry eye sufferers worldwide, about 80% suffer from evaporative dry eye, caused by meibomian gland dysfunction (MGD) and a lipid deficiency of the eye’s natural tear film. The condition leaves patients with too few tears, making the remaining ones feel too salty. Symptoms of evaporative dry eye disease include eye irritation, dryness, redness, tiredness, and visual disturbances.


Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Surgical Headlight
IsoTorch
Adjustable Mobile Barrier
M-458
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.